Imran is a partner at Action Potential Venture Capital in Cambridge, MA and invests in companies that are pioneering bioelectronic medicines, and is looking at select technology enabled healthcare companies. Imran is a Board member of Neuspera Medical, SetPoint Medical and Axon Therapies.
Before joining Action Potential, Imran was in the Worldwide Business Development group of GlaxoSmithKline working in a variety of business development and investing roles. Imran led the establishment of and headed up the Investment Management practice at GSK. The group was tasked with accessing technology and innovation external to GSK by making and managing investments in life science venture capital funds as limited partners and direct investments in biotechs made as part of GSK’s R&D collaborations. During his tenure the group led GSK’s commitments in excess of $200 million in a number of venture capital groups as well as participated in a number of biotech IPOs.
Imran received his bachelor’s degree in finance from Concordia University in Montreal and has trained as a Canadian Chartered Accountant. He serves on the Advisory Board of the new Harvard HealthTech Fellowship and the Board of Ambassadors of the Brooke Charter School a K-8 public charter school network in Boston dedicated to getting underserved students to and through college.
Juan-Pablo is a partner at Action Potential Venture Capital in Palo Alto, CA, and invests in companies that are pioneering bioelectronic medicines and is looking at select technology enabled healthcare companies. Juan-Pablo is a Board member of Saluda Medical, SetPoint Medical, Neuspera Medical, Cala Health, CVRx, and Presidio Medical. He was previously an investor at Morgenthaler Ventures and Lightstone Ventures, where he focused on therapeutic medical devices, digital health, and biopharmaceutical investments. There he served as a Board observer at Ardian (acquired by Medtronic), Twelve (acquired by Medtronic), Nuvaira, Cabochon Aesthetics (acquired by Ulthera/Merz), and Miramar Labs.
Prior to investing, Juan-Pablo led efforts in R&D and Strategy in Medtronic’s CardioVascular Division, including Pipeline Strategy, Business Development, and M&A integration efforts. He was named “Medtronic Inventor of The Year” in 2008, and has 30+ patents, granted or pending. Subsequently, he served on the Global Brand Strategy team at Eli Lilly within the Cardiovascular business.
Juan-Pablo earned an MBA from Stanford GSB, an M.S. in Electrical Engineering from Stanford, and a B.S. in Electrical Engineering from the University of Massachusetts. He serves on the Oversight Committee for Stanford University’s Neuroscience Institute (Wu Tsai), the VC/BD Committee of AdvaMed Accel, the Advisory Board for UCSF’s Rosenman Institute, and is a founding Board Member of LatinxVC. He played Division I men’s lacrosse at the University of Massachusetts, and is originally from Puerto Rico.